

FORTIS FRONTIER PLC

Fortis Frontier PLC
("Fortis Frontier" or the "Company")

Directorate Changes

Fortis Frontier PLC (AIM: FORF) an AIM Rule 15 cash shell (formerly MyHealthChecked PLC) announces the resignation of Non-executive Directors Neil Mesher, Lyn Rees and Amber Vodegel with effect from 30 November 2025, following the completion of the disposal of its trading subsidiary Concepta Diagnostics Limited (as notified on 10 November 2025).

Adam Reynolds, Executive Chairman of Fortis Frontier, said:

"I would like to offer my thanks to Neil, Lyn and Amber, for their contributions over the years, as we built a business with a strong reputation for delivering high quality products and services to retail partners looking to develop their position in the wellness testing market. Now that the Company is an AIM Rule 15 cash shell it is appropriate for us to right-size our Board as we carefully consider the strategic options open to us in order to maximise shareholder value."

For further information contact:

Fortis Frontier PLC

Adam Reynolds, Executive Chairman

www.fortisfrontierplc-ir.com

via Walbrook PR

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Tel: +44 (0)20 3368 3550

Dowgate Capital Limited (Broker)

David Poutney / Russell Cook

Tel: +44 (0)20 3903 7715

Walbrook PR Ltd (Media & IR)

Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or fortisfrontier@walbrookpr.com

Mob: +44 (0)7980 541 893 / +44(0)7407 804 654

About Fortis Frontier PLC

On 10 November 2025 MyHealthChecked PLC completed the disposal of its trading subsidiary, Concepta Diagnostics Limited, becoming an AIM Rule 15 Cash Shell, as defined in the AIM Rules for Companies. On the same day the Company changed its name to Fortis Frontier PLC. The Board is now carefully considering the strategic options available to it in order to maximise shareholder value.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAPPGCUGUPAGGA